STM Article Repository

Aim: The study aimed to analyze the effect of Sitagliptin with Glimepiride during the treatment to improve pancreatic beta-cells in T2DM patients. Beta cells are type of cell found in pancreatic islet and also synthesize, secrete the insulin and amylin. Sitagliptin is found to be maintaining the beta-cells function and glycaemic control in T2DM patients.

Place and Duration of Study: Sample: This study open label randomized T2DM patients, study was conducted at the, Felix multi-specialty hospital, Noida U.P with enrolled patients from 1st Oct, 2017 to 30st Sept, 2019.

Methodology: Randomly diabetes mellitus type-2 (T2DM) patients’ data is collected (110patients) for statistical analysis. For this study T2DM patients enrolled with age of 30-60 years, treated with Sitagliptin and Glimepiride once a day. The baseline of HbA1c >7.0% to <10.5% thus, the performed student t-test is to find out the significance role.

Results: The 110 patients are distributed in two groups: one Sitagliptin user group (n=62) and second Glimepiride user group (n=43). The sitagliptin treatments may also protect also beta cells as pancreas may not able to regenerate beta cell.

Conclusion: The sitagliptin treatments may also protect beta cells as pancreas may not able to regenerate beta cell.